Influence of high cardiovascular risk in asymptomatic people on the duration and cost of sick leave: Results of the ICARIA study

European Heart Journal

Volumn 35, Issue 5, 2014, Pages 299-306

  Calvo Bonacho, Eva ^a   Ruilope, Luis Miguel ^b   Sánchez Chaparro, Miguel Angel ^c   Cerezo, Cesar ^b   Catalina Romero, Carlos ^a   Martínez Muñoz, Paloma ^a   Banegas, José R ^d   Waeber, Bernard ^e   Gonzalez Quintela, Arturo ^f   Zanchetti, Alberto ^g  

^a Ibermutuamur   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSITY OF MÁLAGA   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g UNIVERSITY OF MILAN   (Italy)

Author keywords

Cardiovascular risk; Sick leave; Sickness absence; Work related accidents

Indexed keywords

CARDIOVASCULAR RISK; SICK LEAVE; SICKNESS ABSENCE; WORK-RELATED ACCIDENTS;

ACCIDENTS, OCCUPATIONAL; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CARDIOVASCULAR DISEASES; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; SICK LEAVE; SPAIN; TIME FACTORS; YOUNG ADULT;

EID: 84893853267     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht156     Document Type: Article

References (28)

1. Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27: 1610-1619.
2. Kiiskinen U, Vartiainen E, Puska P, Aromaa A. Long-term cost and life-expectancy consequences of hypertension. J Hypertens 1998;16:1103-1112.
3. KiiskinenU, Vartiainen E, Puska P, PekurinenM. Smoking-related costs among 25 to 59 year-old males in a 19-year individual follow-up. Eur J Public Health 2002;12:145-151.
4. Ramsey S, Summers K, Leong SA, Birnbaum HG, Kemner JE, Greenberg P. Productivity and medical costs of diabetes in a large employerpopulation. Diabetes Care 2002; 25:23-29.
5. Neovius K, Johansson K, Kark M, Neovius M. Obesity status and sick leave: A systematic review. Obes Rev 2009;10:17-27.
6. BurtonWN,Chen C-Y, Schultz AB, EdingtonDW. The prevalence of metabolic syndrome in an employed population and the impact on health and productivity. J Occup Environ Med 2008;50:1139-1148.
7. Tsai SP,Wendt JK, Ahmed FS, Donnelly RP, Strawmyer TR. Illness absence patterns among employees in a petrochemical facility: Impact of selected health risk factors. J Occup Environ Med 2005;47:838-846.
8. Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO. Productivity costs associated with cardiometabolic risk factors clusters in the United States. Value Health 2007;10:443-450.
9. Shultz AB, EdingtonDW. The association between changes in metabolic syndrome and changes in cost in a workplace population. J Occup Environ Med 2009;51: 771-779.
10. Song X, Huse DM,Williams SA, BorockGM, McDonough K,Ozminkowski RJ.Aprojection of the impact of lipid-lowering therapy on high-risk employee disability and medical cost. J Occup Environ Med 2006;48:1014-1022.
11. Wolf M, Siadaty MS, Crowther JQ, Nadler JL,Wagner DL, Cavalieri SL, Elward KS, Bovbjerg VE. Impact of lifestyle intervention on lost productivity and disability control with activity and nutrition (ICAN). J Occup Environ Med 2009;51:139-145.
12. Sampere M, Gimeno D, Serra C, Plana M, Martínez JM, Delclos GL, Benavides FG. Organizational return to work support and sick leave duration: A cohort of Spanish workers with a long-term non-work-related sick leave episode. J Occup Environ Med 2011;53:674-679.
13. Head J, Ferrie JE, Alexanderson K,Westerlund H, Vahtera J, Kivimäki M. Diagnosisspecific sickness absence as a predictor of mortality: The Whitehall II prospective cohort study. BMJ 2008;337:a1469.
14. Lowe LP, Greenland P, Ruth KJ, Dyer AR, Stamler R, Stamler J. Impact of major cardiovascular disease risk factor, particularly in combination, on 22-year mortality in women and men. Arch Intern Med 1998;158:2007-2014.
15. Sánchez-Chaparro MA, Román-García J, Calvo-Bonacho E, Gómez-Larios T, Fernández-Meseguer A, Sáinz- Gutiérrez JC, Cabrera-Sierra M, García-García A, Rueda-Vicente J, Gálvez-Moraleda A, González-Quintela A. Prevalence of cardiovascular risk factors in the Spanish working population. Rev Esp Cardiol 2006;59: 421-430.
16. Conroy RM, Pyörälä K, FitzgeraldAP, Sans S, Menotti A,DeBacker G,DeBacquer D, Ducimetiére P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003;24:987-1003.
17. International Classification of Diseases. 9th Revision, Clinical Modification (ICD-9-CM). Geneva, Switzerland:World Health Organization; 1992.
18. Sánchez ChaparroMA, Calvo Bonacho E, González Quintela A, CabreraM, Sáinz JC, Fernández-Labander C, Quevedo-Aguado L, Gelpi JA, Fernández Meseguer A, Brotons C, de Teresa E, González Santos P, Román García J; ICARIA (Ibermutuamur CArdiovascular RIsk Assessment) Study Group. High cardiovascular risk in Spanish workers. Nutr Metab Cardiovasc Dis 2011;21:231-236.
19. Wijnstok NJ, TwiskJW,Young IS,Woodside JV, McFarlane C, McEneny J, HoekstraT, Murray L, Boreham CA. Inflammation markers are associated with cardiovascular diseases risk in adolescents: The Young Hearts Project 2000. J Adolesc Health 2010; 47:346-351.
20. Karasek D, Vaverkova H, Halenka M, Jackuliakova D, Frysak Z, Slavik L, Novotny D. Prothrombotic markers in asymptomatic dyslipidemic subjects. J Thromb Thrombolysis 2011;31:27-36.
21. Eaton DK, Kann L, Kinchen S, Shanklin S, Flint KH, Hawkins J, HarrisWA, Lowry R, McManus T, Chyen D, Whittle L, Lim C,Wechsler H; Centers for Disease Control and Prevention (CDC). Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ 2012;61:1-162.
22. Isles CG,Walker LM, Beevers GD, Brown I, Cameron HL, Clarke J, Hawthorne V, Hole D, Lever AF, Robertson JW. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986;4:141-156.
23. Lindholm L, Ejlertsson G, Scherstén B.High riskof cerebrocardiovascular morbidity in well treated male hypertensives. A retrospective study of 40-59-year-old hypertensives in a Swedish primary care district. Acta Med Scand 1984;216: 251-259.
24. Benetos A, Thomas F, Bean KE, Guize L. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 2003;21:1635-1640.
25. Law MR, Morris JK,Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-Analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:1665-1683.
26. National Institute for Health and Clinical Excellence (NICE). Hypertension. The clinical management of primary hypertension in adults. Clinical Guideline 127. 2011.www .nice.org.uk/guidance/CG127.
27. Laaksonen M, Piha K, Martikainen P, Rahkonen O, Lahelma E. Health-related behaviors and sickness absence from work. Occup Environ Med 2009;66: 840-847.
28. Sans S, Fitzgerald AP, Royo D, Conroy R, Graham I. Calibrating the SCORE cardiovascular risk chart for use in Spain. Rev Esp Cardiol 2007;60:476-485.